UCB SA (OTCMKTS:UCBJY) Sees Significant Growth in Short Interest

UCB SA (OTCMKTS:UCBJY - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 30,700 shares, a growth of 859.4% from the March 31st total of 3,200 shares. Currently, 0.0% of the company's shares are sold short. Based on an average daily volume of 133,100 shares, the short-interest ratio is presently 0.2 days.

UCB Trading Up 3.0 %

Shares of OTCMKTS UCBJY traded up $2.70 during midday trading on Wednesday, reaching $91.81. 15,476 shares of the stock were exchanged, compared to its average volume of 43,866. The stock has a 50 day moving average price of $89.70 and a 200-day moving average price of $94.14. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. UCB has a 52-week low of $63.58 and a 52-week high of $106.60.

UCB Increases Dividend

The firm also recently announced a dividend, which will be paid on Wednesday, May 14th. Investors of record on Tuesday, April 29th will be paid a $0.4838 dividend. This is a positive change from UCB's previous dividend of $0.46. This represents a yield of 0.62%. The ex-dividend date of this dividend is Monday, April 28th.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.